International Pharmacopsychiatry
January 1, 1973
S Grof, L. Goodman, William A. Richards et al.
212 citations
A psychotherapeutic program using psychedelic compounds (LSD and DPT) was tested in 60 cancer patients to reduce emotional and physical suffering. Ratings by physicians, nurses, family members, and therapists showed significant improvement in depression, anxiety, fear of death, pain, and psychological isolation after treatment. Narcotic use decreased but not significantly. Global distress indexes indicated dramatic improvement in about 29% of patients, moderate improvement in 41.9%, no change in 22.6%, and worsening in 6.4%.
International Pharmacopsychiatry
January 1, 1971
F.s Abuzzahab, B. J. Anderson
47 citations
A review of 31 investigations involving 1,105 patients found that the use of LSD to treat alcoholics produced disappointing overall effectiveness. The studies varied widely: 13 were single large-dose studies without controls, 5 had controls, 4 used multiple low doses without controls, 3 had controls, and 6 were miscellaneous. Single doses ranged from 50 to 800 μg, multiple doses from 25 to 800 μg per dose, with total maximum doses of 100–6,400 μg across up to 6 doses. Follow-up ranged from none to 65 months. Different designs and criteria for improvement made meaningful generalizations difficult.
International Pharmacopsychiatry
August 11, 2017
S. Grof, R.a. Soskin, W.a. Richards et al.
35 citations
A pilot study with 51 alcoholic patients from a state hospital rehabilitation unit tested dipropyltryptamine (DPT) as an adjunct to psychedelic therapy. Evaluation compared pre- and posttreatment results from a battery of psychological tests (MMPI, POI, Raven progressive matrices, PEP, Benton visual retention test) and pretreatment and follow-up ratings by an independent team of social workers. Social workers used 0-10-point scales to measure residential, occupational, and interpersonal adjustment, abstinence, and global adjustment.
International Pharmacopsychiatry
January 1, 1971
R. Fischer, R.M. Hill
7 citations
Ergotropic arousal-inducing drugs—psilocybin, a Ditran-type glycolate, and D-amphetamine—significantly lower spatial distortion thresholds, meaning they interfere with the brain's ability to counter-adapt to optical distortion and maintain an undistorted view of the world. In contrast, the trophotropic arousal-inducing drug chlorpromazine promotes such counter-adaptation, enhancing the optimization of visual information. This interference with optimization occurs independently of the rate at which the distorting stimulus is presented. The optimization itself is considered a cortical perceptual-behavioral interpretive process, while the interference or promotion of it reflects subcortical influences.